2 Dividend Stocks to Buy for a Lifetime of Passive Income

Healthcare giants Merck and Medtronic are highlighted as compelling dividend investments despite individual challenges. Merck's shares are down 4% year-to-date due to concerns over Keytruda's 2028 patent expiry and emerging competition, but the company is mitigating these risks through a strong pipeline, strategic acquisitions, and new drug formulations, while maintaining a 2.96% forward dividend yield and a decade of 71% payout growth. Medtronic, a dividend king with 47 consecutive increases, is driving future growth through its diabetes care innovations, like the MiniMed 780G, and the development of its Hugo robotic-assisted surgery system, positioning it for long-term recovery despite recent revenue headwinds.

Analysis

Merck (MRK) and Medtronic (MDT) are presented as attractive defensive healthcare dividend stocks, despite facing specific near-term headwinds. The overall sentiment for these companies, particularly Medtronic, remains optimistic, focusing on their long-term resilience and capital return policies.

Merck's shares are down 4% year-to-date, primarily due to investor concerns over Keytruda's U.S. patent expiry in 2028 and potential competition. However, Keytruda revenue is projected to grow until 2028 across its numerous indications, and Merck is developing a subcutaneous version retaining exclusivity. The company mitigates risks via a robust pipeline, strategic acquisitions like Acceleron Pharma (yielding Winrevair), and collaborations, supporting its 2.96% forward dividend yield and 71% payout growth over the past decade.

Medtronic, a medical-device specialist, boasts an impressive 47-year streak of dividend increases, underscoring its strong business fundamentals and global presence. Despite recent revenue growth challenges, the company is positioning for long-term recovery through key innovations in its diabetes care segment, such as the MiniMed 780G, and the development of its Hugo robotic-assisted surgery system, addressing increasing demand from an aging population.

Both companies demonstrate strategic initiatives to navigate industry-specific challenges, leveraging diversified product portfolios and innovation to sustain growth. Their consistent dividend records and proactive measures against competitive pressures and patent expirations reinforce their appeal as reliable income investments within the defensive healthcare sector.

Key Decisions for Investors

• Investors should evaluate Merck's long-term growth prospects beyond Keytruda, focusing on its robust pipeline, strategic M&A, and the development of new formulations to sustain its dividend growth.
• Consider Medtronic for its exceptional dividend consistency and long-term growth potential driven by innovations in diabetes care and the Hugo robotic surgery system, despite recent revenue headwinds.
• For income-focused portfolios, both MRK and MDT offer defensive characteristics and reliable dividend payouts, making them suitable for long-term holding amidst economic uncertainty.